we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Company profile
Ticker
ATRA
Exchange
Website
CEO
Pascal Touchon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Atara Biotherapeutics Australia • Atara Biotherapeutics Ireland Limited • Atara Biotherapeutics Switzerland GmbH ...
ATRA stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
12 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
28 Mar 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
424B5
Prospectus supplement for primary offering
9 Jan 24
8-K
Entry into a Material Definitive Agreement
9 Jan 24
8-K
Cost Associated with Exit or Disposal Activities
8 Jan 24
S-8
Registration of securities for employees
3 Jan 24
8-K
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
20 Dec 23
Transcripts
ATRA
Earnings call transcript
2023 Q3
1 Nov 23
ATRA
Earnings call transcript
2022 Q3
9 Nov 22
ATRA
Earnings call transcript
2022 Q2
8 Aug 22
ATRA
Earnings call transcript
2022 Q1
6 May 22
ATRA
Earnings call transcript
2021 Q4
1 Mar 22
ATRA
Earnings call transcript
2021 Q3
4 Nov 21
ATRA
Earnings call transcript
2021 Q2
10 Aug 21
ATRA
Earnings call transcript
2021 Q1
5 May 21
ATRA
Earnings call transcript
2020 Q4
2 Mar 21
ATRA
Earnings call transcript
2020 Q3
10 Nov 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 64.94 mm | 64.94 mm | 64.94 mm | 64.94 mm | 64.94 mm | 64.94 mm |
Cash burn (monthly) | (no burn) | 126.92 k | 23.27 mm | 24.32 mm | 17.12 mm | 16.62 mm |
Cash used (since last report) | n/a | 872.26 k | 159.94 mm | 167.11 mm | 117.63 mm | 114.23 mm |
Cash remaining | n/a | 64.06 mm | -95.00 mm | -102.18 mm | -52.69 mm | -49.29 mm |
Runway (months of cash) | n/a | 504.8 | -4.1 | -4.2 | -3.1 | -3.0 |
Institutional ownership, Q3 2023
73.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 108 |
Opened positions | 11 |
Closed positions | 19 |
Increased positions | 42 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 113.33 bn |
Total shares | 87.57 mm |
Total puts | 50.20 k |
Total calls | 977.70 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Baupost | 9.77 mm | $14.47 mm |
JPM JPMorgan Chase & Co. | 8.67 mm | $12.83 bn |
Wasatch Advisors | 8.40 mm | $12.43 bn |
BLK Blackrock | 7.70 mm | $11.39 bn |
Vanguard | 6.61 mm | $9.78 bn |
Maverick Capital | 6.29 mm | $9.31 bn |
Redmile | 6.28 mm | $9.30 bn |
GS Goldman Sachs | 4.12 mm | $6.10 bn |
D. E. Shaw & Co. | 3.91 mm | $5.79 bn |
STT State Street | 2.52 mm | $3.73 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Fust Matthew K | Common Stock | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 259,000 |
31 Mar 24 | William K Heiden | Common Stock | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 359,000 |
31 Mar 24 | Maria Grazia Roncarolo | Common Stock | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 238,500 |
31 Mar 24 | Gallagher Carol Giltner | Common Stock | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 629,608 |
31 Mar 24 | Ameet Mallik | Common Stock | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 227,500 |
News
12 Health Care Stocks Moving In Monday's After-Market Session
8 Apr 24
Stifel Maintains Hold on Atara Biotherapeutics, Lowers Price Target to $2.3
1 Apr 24
Atara Biotherapeutics Q4 EPS $(0.56) Misses $(0.48) Estimate, Sales $4.25M Miss $11.55M Estimate
28 Mar 24
Atara Biotherapeutics: Q4 Earnings Insights
28 Mar 24
12 Health Care Stocks Moving In Monday's After-Market Session
18 Mar 24
Press releases
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
5 Apr 24
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
28 Mar 24
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
29 Feb 24
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
28 Feb 24
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
14 Feb 24